

## Special Issue

# Inequality in Immunization 2023

### Message from the Guest Editors

While overall in the world, immunization rates stagnated prior to the COVID-19 pandemic, and declined in 2020 and 2021, this is neither uniformly the case for all types of vaccines, nor for all population sub-groups for any individual vaccine. In this Special Issue, we will explore the latest evidence on various types of immunization across the life course at global, regional, national and subnational levels. We encourage submissions that explore various dimensions of inequality—such as economic status, subnational geographic regions, sex, maternal education—and other categories (like migrant status or occupation), or that shed greater analytical or methodological light on priority population subgroups, namely, populations facing gender barriers, rural residents, the urban poor, and populations living in conflict areas. We encourage submissions that compare various country contexts or that assess trends over time, and those that draw from geographies where the evidence has been limited to date, such as Low and Middle-Income Country contexts. Communications that describe the impacts of inequality monitoring of immunization are also welcome.

---

### Guest Editors

Dr. Ahmad Reza Hosseinpoor

Dr. M. Carolina Danovaro

Dr. Devaki Nambiar

Dr. Aaron Wallace

Dr. Hope L. Johnson

---

### Deadline for manuscript submissions

closed (28 February 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/134476](https://mdpi.com/si/134476)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).